Aims: The process of differential diagnosis between epithelioid mesothelioma and lung adenocarcinoma has been progressing; however, there are no absolute immunohistochemical markers with which to definitively diagnose epithelioid mesothelioma. The aim of this study was to search for a novel negative marker of epithelioid mesothelioma.
Mucin 21 is a novel, negative immunohistochemical marker for epithelioid mesothelioma for its differentiation from lung adenocarcinoma Aims: The process of differential diagnosis between epithelioid mesothelioma and lung adenocarcinoma has been progressing; however, there are no absolute immunohistochemical markers with which to definitively diagnose epithelioid mesothelioma. The aim of this study was to search for a novel negative marker of epithelioid mesothelioma.
Methods and results:
We immunohistochemically studied the applicability of mucin 21 (MUC21), which was identified in our previous study, as a novel, negative diagnostic marker for epithelioid mesothelioma. Seventy epithelioid mesotheliomas and 70 lung adenocarcinomas were investigated for the expression of MUC21, along with other previously reported markers, by the use of immunohistochemistry. MUC21 was expressed in only two of the 70 (3%) epithelioid mesotheliomas, as compared with 67 of the 70 (96%) lung adenocarcinomas. The sensitivity, specificity and accuracy of negative MUC21 expression for differentiating epithelioid mesothelioma from lung adenocarcinoma were 97%, 96%, and 96%, respectively; these are similar to those of carcinoembryonic antigen and claudin-4, and better than those
Introduction
Malignant mesothelioma results in highly aggressive tumours, and its prognosis is extremely poor. 1 The worldwide incidence of malignant mesothelioma is rising, with a predicted peak before 2030, particularly in developed countries. 2 Treatments for mesothelioma have been developed, and multimodal therapies, including surgery, chemotherapy, and radiotherapy, have been adopted. 3, 4 In order to provide appropriate management, an early and accurate pathological diagnosis is essential.
Malignant mesothelioma is classified according to three histological subtypes: epithelioid, sarcomatoid, and biphasic. 5 The most common type is epithelioid, and patients with this histological type have the best prognosis. [6] [7] [8] Epithelioid mesothelioma has a wide range of differentiation and shows various histological patterns, including tubulopapillary, papillary, micropapillary, trabecular, solid, and pleomorphic. 9 Owing to the similarity of the histomorphological patterns between epithelioid mesothelioma and lung adenocarcinoma, 10 epithelioid mesothelioma is occasionally misdiagnosed as lung adenocarcinoma and vice versa. In our previous study, we reviewed the pathological diagnoses of patients who died from malignant mesothelioma in Japan, and reported that lung adenocarcinomas were most frequently misdiagnosed as malignant mesothelioma. 11 Therefore, immunohistochemical markers are important for the precise diagnosis of epithelioid mesothelioma. Currently, the International Mesothelioma Interest Group (iMig) recommends that at least two mesothelial and two carcinoma markers should be included in the panel: calretinin, podoplanin (D2-40), Wilms tumour 1 and cytokeratin 5/6 as positive mesothelioma markers, and carcinoembryonic antigen (CEA), claudin-4, thyroid transcription factor-1 (TTF-1) and napsin-A as positive lung adenocarcinoma markers. 12 Although these immunohistochemical markers have advanced our diagnostic capabilities, it is difficult to obtain a definitive diagnosis in some cases with exceptional antigen expression patterns.
Recently, we conducted a gene expression analysis using formalin-fixed paraffin-embedded (FFPE) sections of six epithelioid mesothelioma and six lung adenocarcinoma samples, and proposed intelectin-1 and disabled homologue 2 (DAB2) as two novel positive immunohistochemical markers for epithelioid mesothelioma. We also identified low expression of mucin 21 (MUC21) and other markers in epithelioid mesothelioma, as compared with lung adenocarcinoma, which was published as supplementary data. 13 In this study, which is a continuation of the previous study, we evaluated the utility of MUC21 expression as an immunohistochemical marker to differentiate epithelioid mesothelioma from lung adenocarcinoma.
Materials and methods
We reanalysed the microarray gene expression data for epithelioid mesothelioma and lung adenocarcinoma that we had published previously, 13 and determined the differentially expressed genes, on the basis of those that showed more than a two-fold change. Statistical analyses were performed with the Subio Platform software (Subio, Amami-shi, Japan).
To validate MUC21 expression in epithelioid mesothelioma and lung adenocarcinoma, MUC21 protein expression was analysed by western blotting. Total protein from a lung adenocarcinoma cell line (A549) and the two mesothelioma cell lines (ACC-MESO-1 and CRL-5915) was extracted with a cell lysis protein extraction reagent (Cell-LyEX1 kit; TOYO B-Net, Tokyo, Japan). Approximately 25 lg of protein was subjected to electrophoresis via a Novex 10% Bis-Tris gel with a Bolt mini gel tank (Thermo Fisher Scientific, Yokohama, Japan). The proteins were then transferred to a Hybond-P poly(vinylidene difluoride) membrane (GE Healthcare, Little Chalfont, UK) by use of a Mini Blot Module (Thermo Fisher Scientific). After being treated with blocking buffer, the transfer membrane was incubated with an anti-MUC21 antibody (1:500, rabbit polyclonal; Atlas Antibodies, Bromma, Sweden) overnight at 4°C. This was followed by incubation with streptavidin-labelled anti-mouse or anti-rabbit secondary antibodies (Cell Signaling Technology, Tokyo, Japan) and Immunostar LD (Wako Pure Chemicals, Tokyo, Japan) as a chemiluminescence detection reagent. An anti-glyceraldehyde-3-phosphate dehydrogenase antibody (1:1000, rabbit monoclonal, 2118; Cell Signaling Technology) was used as a control. The blot membrane was captured by scanning with a CDiGit Blot Scanner (LI-COR Biosciences, Lincoln, NE, USA) for detection of the proteins of interest.
P A T I E N T S A N D H I S T O L O G I C A L S A M P L E S
This study included 70 epithelioid mesothelioma and 70 lung adenocarcinoma pathological specimens from the tissue archives of the Department of Pathology, Hiroshima University. Mesothelioma specimens were derived from patients who had undergone videoassisted thoracoscopic biopsy, pleurectomy/decortication or extrapleural pneumonectomy between 2005 and 2017. In all 29 (41%) cases in which videoassisted thoracoscopic biopsies were performed, they were conducted under general anaesthesia and provided adequate tissues for histological diagnosis. All of the lung adenocarcinoma specimens were obtained by surgical resection between 2010 and 2017. All of the histological sections were evaluated and reclassified by four pathologists (Y.K., K.K., V.J.A., and Y.T.). Pathological diagnosis was determined by the use of histological features and immunohistochemical marker panels according to the consensus guidelines established by the 2017 iMig 12 and 2015 World Health Organisation histological classification of lung tumours.
14 Epithelioid mesotheliomas included 29 (41%) cases with a tubulopapillary pattern and 41 (59%) cases with a solid pattern. Six of the epithelioid mesotheliomas with a solid pattern also showed a tubulopapillary pattern. Lung adenocarcinomas included 37 (53%) cases of papillary/acinar-predominant adenocarcinoma and 33 (47%) cases of solid-predominant adenocarcinoma. Lepidic lung adenocarcinomas were not included in this study.
This study was performed in accordance with the Ethics Guidelines for Human Genome/Gene Research enacted by the Japanese government for the collection of tissues specimens, and was approved by the institutional ethics review committee (Hiroshima University E-974).
Immunohistochemistry was performed on 3-lm tissue sections from the most representative FFPE blocks of the epithelioid mesotheliomas and lung adenocarcinomas. We used a Ventana BenchMark GX immunohistochemical autostainer (Ventana, Roche Diagnostics, Tokyo, Japan) with a Ventana ultraView Universal DAB Detection Kit (Ventana) as a detection system. The antigen was retrieved by the use of cell condition buffer (CC1; Ventana) at 99°C for 60 min. An anti-MUC21 antibody, diluted 50 times with SignalStain Antibody diluent (Cell Signaling Technology), was used as the primary antibody. Sections were incubated with the primary antibody for 2 h at room temperature, and this was followed by amplification with an Amplification Kit (Ventana). CEA, claudin-4, TTF-1, napsin-A and mucin 4 (MUC4) immunohistochemistry was performed as previously described. 
Results

D I F F E R E N T I A L G E N E E X P R E S S I O N B E T W E E N E P I T H E L I O I D M E S O T H E L I O M A A N D L U N G A D E N O C A R C I N O M A
A scatter plot diagram showed 27 076 transcripts in epithelioid mesothelioma and lung adenocarcinoma that showed up-regulation of various genes in lung adenocarcinoma ( Figure 1A) . Of the 58 genes that were differentially expressed, on the basis of an at least two-fold increase between epithelioid mesothelioma and lung adenocarcinoma, 35 were up-regulated in epithelioid mesothelioma and 23 were up-regulated in lung adenocarcinoma ( Figure 1B) . MUC21 expression showed very low expression signals in all six epithelioid mesotheliomas, and was present in four of the six lung adenocarcinoma samples ( Figure 1C ).
W E S T E R N B L O T A N A L Y S I S
Western blot analysis showed MUC21 expression in A549 lung adenocarcinoma cells, whereas no expression was observed in ACC-MESO-1 and CRL-5915 mesothelioma cells ( Figure 1D ).
The expression profiles of MUC21 and the other markers of lung adenocarcinoma are summarised in Table 1 Among 67 lung adenocarcinomas with positive MUC21 expression, 25 showed an immunohistochemical score of 3+, 27 showed an immunohistochemical score of 2+, and 15 showed an immunohistochemical score of 1+. Among 37 papillary/acinar-predominant lung adenocarcinomas, 16 (43%) showed an immunohistochemical score of 3+, 11 (30%) showed an immunohistochemical score of 2+, eight (22%) showed an immunohistochemical score of 1+, and two (5%) showed no MUC21 expression. Among 33 solid-predominant adenocarcinomas, nine (27%) showed an immunohistochemical score of 3+, 16 (49%) showed an immunohistochemical score of 2+, seven (21%) showed an immunohistochemical score of 1+, and one (3%) showed no MUC21 expression.
All lung adenocarcinomas with negative immunoreactivity for CEA (two cases), claudin-4 (two cases), TTF-1 (five cases), napsin-A (12 cases), or MUC4 (17 cases) showed positive immunoreactivity for MUC21 (Table 2) .
Among the eight lung adenocarcinomas with an immunohistochemical score of 1+ for CEA, two showed an immunohistochemical score of 3+ for MUC21, four showed an immunohistochemical score of 2+ for MUC21, and two showed an immunohistochemical score of 1+ for MUC21. Two lung adenocarcinomas with an immunohistochemical score of +1 for claudin-4 and three cases with an immunohistochemical score of 1+ for TTF-1 showed an immunohistochemical score of 2+ or 3+ for MUC21. Five of the seven lung adenocarcinomas with an immunohistochemical score of 1+ for napsin-A showed an immunohistochemical score of 2+ or 3+ for MUC21. Seventeen of the 22 lung adenocarcinomas with an immunohistochemical score of 1+ for MUC4 showed an immunohistochemical score of 2+ or 3+ for MUC21 (Table 3) .
C E A , C L A U D I N -4 , T T F -1 , N A P S I N -A A N D M U C 4 E X P R E S S I O N
Carcinoembryonic antigen expression, TTF-1 expression, napsin-A expression and MUC4 expression were absent in all of the epithelioid mesotheliomas. Weak expression of claudin-4 was present in two (3%) of the epithelioid mesotheliomas. In contrast, CEA expression, claudin-4 expression and TTF-1 expression were present in 68 (97%), 68 (97%) and 65 (93%) lung adenocarcinomas, respectively, and the majority of them showed an immunohistochemical score of 3+. Napsin-A expression and MUC4 expression were present in 58 (83%) and 53 (76%) lung adenocarcinomas, respectively.
S E N S I T I V I T Y , S P E C I F I C I T Y , P P V , N P V A N D D I A G N O S T I C A C C U R A C Y O F M U C 2 1 A N D O T H E R I M M U N O H I S T O C H E M I C A L M A R K E R S
The sensitivity, specificity, PPV, NPV and accuracy of negative MUC21 expression and other markers for differentiating epithelioid mesothelioma from lung adenocarcinoma are shown in Table 4 . The sensitivity of negative MUC21 expression (97%) for differentiating epithelioid mesothelioma from lung adenocarcinoma was lower than that of negative CEA, TTF-1, napsin-A and MUC4 expression. However, the specificity of negative MUC21 expression (96%) was better than that of negative TTF-1, napsin-A and MUC4 expression, and comparable to that of negative CEA and claudin-4 expression.
Discussion
For the adequate treatment of malignant pleural mesothelioma, pathological diagnostic techniques and tools must continue to evolve, especially in immunohistochemistry. Many immunohistochemical markers are available to differentiate epithelioid mesothelioma from lung adenocarcinoma. Recently, we reported three novel positive markers for epithelioid mesothelioma: glypican-1, 16 intelectin-1, and DAB2. 13 Glypican-1 showed extremely high sensitivity (100%) and specificity (97%) for the differentiation of epithelioid mesothelioma from lung adenocarcinoma. The sensitivity of glypican-1 was comparable to that of calretinin and D2-40, and its specificity was superior to that of calretinin and D2-40.
On the other hand, negative markers of epithelioid mesothelioma are equally important. Thus, we focused on a novel positive marker for lung adenocarcinoma. In our previous report on intelectin-1 and DAB2, we mentioned that the mRNA transcripts of MUC21, CEACAM6, NAPSA, MUC4 etc. were upregulated in lung adenocarcinoma. CEACAM6 and NAPSA are known to encode CEA and napsin-A, respectively, and we recently reported the efficacy of MUC4 as a negative immunohistochemical marker for the differentiation of epithelioid mesothelioma from non-small-cell lung carcinoma, either adenocarcinoma or squamous cell carcinoma. 15 Reanalysis of the microarray data from a previous study 13 was performed to generate the scatter plot, line graph and hierarchical clustering of statistically significant genes with more than a two-fold change between epithelioid mesothelioma and lung adenocarcinoma. MUC21 was identified as a novel gene of interest for further study of its utility as a basis for a negative immunohistochemical marker of epithelioid mesothelioma to differentiate it from lung adenocarcinoma.
MUC21, formerly called epiglycanin, was reported as a glycoprotein expressed on the surfaces of highly malignant TA3-Ha cells, 17, 18 which constitute a variant of TA3 cells; the latter were isolated as mammary carcinoma cells that originated from a spontaneous tumour in A/HeHa mice in 1949. 19 Recently, Itoh et al. identified a human counterpart of mouse mucin 21 (Muc21), termed MUC21. 20 They reported mRNA expression of epiglycanin/MUC21 in the lung, thymus, and colon. They also detected MUC21 expression in the cytoplasm of bronchial epithelial cells and lung adenocarcinoma tissues by using an antibody against the cytoplasmic tail of MUC21 that they had developed.
In the present study, MUC21 expression was validated by western blot analysis, and immunohistochemical analysis of MUC21 in epithelioid mesothelioma and lung adenocarcinoma was performed. Unlike the previous study, 20 our study showed no immunohistochemical expression of MUC21 in normal lung tissues, and its positive expression in lung adenocarcinoma was localised to the membranes of the tumour cells in our study. This discrepancy could be explained by the antibody used in this study, which was specific for a different epitope of the antigen. Itoh et al. 20 used a polyclonal antibody specific for the cytoplasmic tail (termed anti-MUC21CT antiserum). However, we used the commercially available polyclonal anti-MUC21 antibody.
This antibody showed membranous positivity in oesophageal epithelial cells and cytoplasmic positivity in the parietal cells of the stomach, as reported in the Human Protein Atlas database (https://www.proteina tlas.org/ENSG00000204544-MUC21).
The sensitivity and specificity of negative MUC21 expression for the differentiation of epithelioid mesothelioma from lung adenocarcinoma were 97% and 96%, respectively. The sensitivity was slightly inferior to that of negative CEA, TTF-1, napsin-A or MUC4 expression. However, the specificity was better than that of negative TTF-1, napsin-A or MUC4 expression. The diagnostic accuracy of negative MUC21 expression (96%) was similar to that of CEA, claudin-4 and TTF-1 expression, and better than that of negative napsin-A or MUC4 expression. The PPV of negative MUC21 expression (96%) was similar to that of negative CEA or claudin-4 expression, and better than that of negative TTF-1, napsin-A or MUC4 expression. The NPVs were similar for negative MUC21 expression and negative expression of the other markers. On the assumption that the actual prevalence of lung adenocarcinoma far exceeds that of epithelioid mesothelioma, the PPV of negative MUC21 expression will be much lower than in the present study. However, the PPVs of other markers, including CEA and claudin-4, are also reduced in similar ways.
An immunohistochemical score of 1+ was more frequently observed for MUC21 (15 cases) than for CEA (eight cases), claudin-4 (two cases), and TTF-1 (three cases). Therefore, the evaluation of MUC21 expression needs careful observation. The number of papillary/acinar-predominant lung adenocarcinomas (27, 73%) with an immunohistochemical score of 3+ or 2+ for MUC21 was similar to the number of solid- predominant adenocarcinomas (25, 76%) with an immunohistochemical score of 3+ or 2+, suggesting that the histological pattern of lung adenocarcinoma is not responsible for the difference in immunohistochemical score.
We also found MUC21 expression in the lung adenocarcinomas with no expression of either CEA, claudin-4, TTF-1, napsin-A, or MUC4. Moreover, two lung adenocarcinomas, one negative for both CEA and claudin-4, and the other negative for both CEA and TTF-1, had MUC21 expression. Various lung adenocarcinomas showing an immunohistochemical score of only +1 for CEA, claudin-4, TTF-1, napsin-A or MUC4 showed an immunohistochemical score of 2+ or 3+ for MUC21. Thus, by using MUC21, we can reduce the number of falsenegative cases of lung adenocarcinoma. Therefore, the addition of MUC21 immunohistochemistry will aid in the precise diagnosis of epithelioid mesothelioma.
The immunohistochemical findings of epithelioid mesothelioma with positive MUC21 expression (two cases) or claudin-4 expression (two cases) shown in Figures S1 and S2 are compatible with the diagnosis of epithelioid mesothelioma. Similarly, the immunohistochemical findings of two lung adenocarcinomas without claudin-4 expression shown in Figure S3 are compatible with the diagnosis of lung adenocarcinoma. Therefore, immunohistochemical findings are not always perfect, and rare exceptional cases show aberrant immunohistochemical findings.
In conclusion, we propose MUC21, identified by gene expression analysis, as an additional novel negative marker for epithelioid mesothelioma for the differentiation of epithelioid mesothelioma from lung adenocarcinoma. Further validation in other laboratories is required to support our findings.
